Voyager Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Voyager Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $6.35M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $1.15M | Mar 14, 2018 |
| FY2017 | Jun 30, 2017 | $1.18M | Mar 14, 2018 |
| FY2017 | Mar 31, 2017 | $1.46M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $2.36M | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $3.31M | Mar 14, 2018 |
| FY2017 | Jun 30, 2016 | $3.72M | Mar 14, 2018 |
| FY2017 | Mar 31, 2016 | $4.83M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $4.94M | Mar 15, 2017 |
| FY2016 | Sep 30, 2015 | $4.94M | Mar 15, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.37M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $80.00M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $250.01M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $40.91M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $37.42M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $171.13M | Mar 7, 2023 |
| FY2019 | Dec 31, 2019 | $32.67M | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | $20.43M | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | $46.09M | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | $5.20M | Mar 3, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($119.72M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($65.00M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $132.33M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($46.41M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($71.20M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $36.74M | Mar 7, 2023 |
| FY2019 | Dec 31, 2019 | ($12.57M) | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | ($15.01M) | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | $11.15M | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | ($27.17M) | Mar 3, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($131.84M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($83.29M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $122.01M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($50.84M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($73.62M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $27.38M | Mar 7, 2023 |
| FY2019 | Dec 31, 2019 | ($13.77M) | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | ($17.81M) | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | $9.19M | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | ($29.29M) | Mar 3, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.67M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $127.37M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $92.17M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $60.76M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $73.79M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $108.75M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $119.74M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $64.91M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $62.26M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $42.25M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($132.47M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($15.31M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $77.92M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($12.51M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | ($53.53M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($96.72M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $48.67M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | ($15.89M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($61.35M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($42.48M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.60M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $3.52M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $3.26M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $2.49M | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.61M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $12.10M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $7.72M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $4.31M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.99M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $5.03M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $252.28M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $393.05M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $351.28M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $159.36M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $193.86M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $261.58M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $354.76M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $177.03M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $184.48M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $189.57M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.20M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $93.29M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $114.96M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $100.34M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $98.80M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $107.26M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $255.25M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $130.58M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $50.43M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $53.64M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.08M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $299.76M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $236.32M | Mar 9, 2026 |
| FY2025 | Dec 31, 2022 | $59.02M | Mar 9, 2026 |
| FY2024 | Dec 31, 2021 | $95.06M | Mar 11, 2025 |
| FY2023 | Dec 31, 2020 | $154.32M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $99.51M | Mar 7, 2023 |
| FY2021 | Dec 31, 2018 | $46.45M | Mar 8, 2022 |
| FY2020 | Dec 31, 2017 | $134.05M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $135.92M | Mar 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($445.91M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($326.18M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($261.18M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($393.51M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($347.10M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($275.91M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($312.65M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($269.05M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($160.71M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($90.02M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.30M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $71.37M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $68.80M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $98.96M | Feb 28, 2024 |
| FY2023 | Dec 31, 2021 | $117.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $104.44M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $86.04M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $46.86M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $31.53M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $36.64M | Feb 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | (2) | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | (2) | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.05M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 54.73M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 44.04M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | 38.61M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 37.92M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 37.37M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 36.87M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 32.36M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 31.57M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 25.60M | Mar 14, 2018 |